Can you provide me notes of HTN latest form basics to clinicals
Reading File
Finding Sources
Searching PubMed
"hypertension" AND "guidelines"
Reading File
Finding Sources
Reading Article
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information. Let me compose the full HTN notes.
Hypertension (HTN) - Comprehensive Notes: Basics to Clinicals
Updated to 2025 AHA/ACC Guidelines (PMID: 40811516) and 2024 ESC Guidelines (PMID: 39210715)
1. DEFINITION & CLASSIFICATION
BP Classification (2017/2025 AHA/ACC - Adults)
| Category | SBP | DBP | |
|---|---|---|---|
| Normal | <120 mmHg | and | <80 mmHg |
| Elevated | 120-129 mmHg | and | <80 mmHg |
| Stage I HTN | 130-139 mmHg | or | 80-89 mmHg |
| Stage II HTN | ≥140 mmHg | or | ≥90 mmHg |
Children ≥13 years: same as adults. Children 1-12 years: percentile-based (Stage I = ≥95th percentile; Stage II = ≥95th + 12 mmHg or ≥140/90).
2024 ESC maintains the older threshold: ≥140/90 mmHg = hypertension (with "elevated normal" = 130-139/85-89 mmHg).
Key BP Phenotypes
- White coat HTN: elevated office BP but normal out-of-office readings (ambulatory/home BP)
- Masked HTN: normal office BP but elevated out-of-office readings - carries increased CVD risk
- Resistant HTN: uncontrolled BP despite ≥3 antihypertensives at optimal doses (one being a diuretic)
- Refractory HTN: uncontrolled on ≥5 agents
- Pseudoresistant HTN: apparent resistance due to poor adherence, white coat effect, or incorrect measurement
Hypertensive Crisis
- Emergency: severely elevated BP (usually >180/120) WITH acute target organ damage (TOD) - requires immediate IV treatment
- Urgency: severely elevated BP WITHOUT TOD - can be managed orally, gradual reduction over 24-48h
2. EPIDEMIOLOGY
- HTN affects ~1.28 billion adults worldwide; a leading cause of premature cardiovascular death
- Lifetime risk approaches 90% for individuals living to age 80-85
- Race/ethnicity: higher prevalence and severity in Black populations (earlier onset, greater TOD)
- HTN is present in ~85% of adults with diabetes; the two conditions are highly colinear
- Only ~50% of hypertensive patients have controlled BP globally
3. PATHOPHYSIOLOGY
Key Equation
BP = Cardiac Output (CO) × Total Peripheral Resistance (TPR)
In chronic established HTN:
- CO is typically normal
- TPR is elevated (autoregulatory response to maintain tissue perfusion)
- Increased TPR is often a consequence - not the primary cause - of elevated BP
Renal-Body Fluid Feedback (Guyton's Concept)
The kidney is central to long-term BP regulation via pressure natriuresis - as BP rises, sodium and water excretion increases, reducing volume and resetting BP. HTN occurs when this pressure-natriuresis curve is shifted rightward, requiring a higher BP to maintain sodium balance.
Causes of impaired renal pressure natriuresis:
- Nephron loss (reduced filtration surface area)
- Increased preglomerular resistance (patchy = salt-sensitive; generalized = salt-insensitive)
- Reduced glomerular filtration coefficient (Kf)
- Increased renal tubular reabsorption (mineralocorticoid excess, Ang II excess)
RAAS (Renin-Angiotensin-Aldosterone System)
- A key function of RAAS is to allow wide variations in sodium intake without large BP fluctuations
- Reduced RAAS responsiveness (e.g., mineralocorticoid excess, Liddle syndrome) impairs suppression of renin during high sodium intake → salt-sensitive HTN
- Focal nephrosclerosis → patchy preglomerular vasoconstriction → ischemic nephrons hypersecrete renin
Neurohormonal Mechanisms
| System | Role in HTN |
|---|---|
| RAAS (Ang II) | Vasoconstriction, sodium retention, aldosterone release, sympathetic activation |
| Sympathetic NS | Increases CO, promotes renal sodium retention via α1-receptors, vasoconstriction |
| Endothelin-1 (ET-1) | Potent vasoconstrictor; ET-1 especially mediates salt-sensitive HTN |
| Nitric Oxide (NO) deficiency | Impairs renal pressure natriuresis; oxidative stress inactivates NO |
| Atrial Natriuretic Peptide (ANP) | Counter-regulatory; reduces preload, promotes natriuresis |
| Aldosterone | Increases distal tubule Na+ reabsorption → volume expansion → HTN |
Autoregulation Shift in Chronic HTN
In chronic HTN, the autoregulation curve shifts to higher BPs - hypertensive patients tolerate higher BP before organ damage. This is why rapid BP lowering can cause ischemia in chronically hypertensive patients (brain, kidney).
Obesity-Related HTN Mechanisms
- Renal sympathetic nerve activation → sodium retention
- RAAS activation (adipose-derived renin, angiotensinogen)
- Hyperinsulinemia → renal tubular sodium reabsorption
- ~78% of male primary HTN and ~65% of female primary HTN attributed to excess weight (Framingham)
Salt Sensitivity
- More common in older patients and in Black patients
- Characterized by rightward shift in pressure-natriuresis curve, low renin
- Caused by: aldosterone excess, high Ang II, Liddle syndrome, nephron loss
4. ETIOLOGY
Primary (Essential) HTN (~90-95%)
- No identifiable single cause
- Polygenic; influenced by lifestyle, diet (sodium, potassium), obesity, age, stress
Secondary HTN (<10%)
When to suspect: severe/resistant HTN, onset before age 30 in non-obese patient, acute rise from a previously stable baseline, onset before puberty, HTN with associated electrolyte abnormalities
| Category | Condition | Key Clue |
|---|---|---|
| Renal parenchymal | CKD, glomerulonephritis, polycystic kidney disease, diabetic nephropathy | Elevated Cr, proteinuria, abnormal UA |
| Renovascular | Renal artery stenosis (FMD in young; atherosclerosis in elderly) | Abdominal bruit (diastolic), acute ↑Cr after ACEI/ARB |
| Renal artery stenosis | Fibromuscular dysplasia - "string of beads" on angiography | Young women; up to 20% of resistant HTN |
| Coarctation of aorta | Congenital narrowing of aorta | BP discordance upper vs. lower limbs; rib notching on CXR |
| Primary aldosteronism | Bilateral hyperplasia or adrenal adenoma (Conn's) | HTN + hypokalemia + metabolic alkalosis; aldosterone:renin ratio >30 (~10% of hypertensive patients) |
| Pheochromocytoma | Catecholamine-secreting tumor | Episodic headache, palpitations, diaphoresis, flushing ("5 P's") |
| Cushing's syndrome | Cortisol excess | Central obesity, thin skin, ecchymoses, osteoporosis, striae |
| Hypothyroidism | ↓Thyroid function | Raised DBP; cold intolerance, constipation; ~20% of hypothyroid patients; resolves with T4 replacement |
| Hyperthyroidism | ↑Thyroid function | Isolated ↑SBP (wide pulse pressure); treat underlying + beta-blockers |
| Acromegaly | GH excess | Arthralgias, macroglossia, jaw enlargement, headache |
| Hypercalcemia | Any cause | Direct Ca-mediated ↑SVR; avoid thiazides |
| Sleep apnea | OSA | Nondipping pattern; snoring, daytime somnolence |
| Drugs/toxins | NSAIDs, OCP, glucocorticoids, sympathomimetics, cocaine, amphetamines, cyclosporine, licorice (apparent mineralocorticoid excess) | Medication history |
| Vasculitis | PAN, Takayasu arteritis, GCA, Kawasaki | Systemic features |
5. DIAGNOSIS & EVALUATION
BP Measurement (Proper Technique)
- Patient seated, back supported, feet flat, arm at heart level, 5-min rest before measurement
- Use correct cuff size (bladder encircling 80% of arm circumference)
- Average ≥2 readings on ≥2 separate occasions
- Check both arms initially (>10 mmHg difference suggests peripheral artery disease)
- In elderly: check orthostatic BP
Out-of-Office BP Monitoring
- Ambulatory BP Monitoring (ABPM): gold standard; identifies white coat HTN, masked HTN, nondipping
- Home BP Monitoring (HBPM): average of AM + PM readings over 5-7 days
Nondipping BP
- Normal: nocturnal BP dips ≥10% from daytime
- Nondippers have increased CVD/CKD risk
- Associated with: OSA, CKD, autonomic dysfunction, diabetes
Initial Workup (All Hypertensive Patients)
History: duration, prior readings, family history, medications, lifestyle, symptoms of secondary causes
Physical exam: fundoscopy (hypertensive retinopathy), cardiovascular exam, bruits, BMI, waist circumference
Basic labs: BMP (electrolytes, BUN, Cr), fasting glucose, lipid panel, urinalysis + microalbumin, CBC
ECG: LV hypertrophy, arrhythmias
Echocardiogram: if suspected LVH or cardiac dysfunction
Physical exam: fundoscopy (hypertensive retinopathy), cardiovascular exam, bruits, BMI, waist circumference
Basic labs: BMP (electrolytes, BUN, Cr), fasting glucose, lipid panel, urinalysis + microalbumin, CBC
ECG: LV hypertrophy, arrhythmias
Echocardiogram: if suspected LVH or cardiac dysfunction
Target Organ Damage (TOD) Assessment
| Organ | Finding |
|---|---|
| Heart | LVH, CAD, HF |
| Brain | Stroke, TIA, lacunar infarcts |
| Kidney | CKD, microalbuminuria, proteinuria |
| Eyes | Hypertensive retinopathy (grades I-IV) |
| Peripheral vessels | PAD |
Keith-Wagener-Barker Retinopathy Grading
- Grade I: arteriovenous (AV) nipping, silver wiring
- Grade II: definite AV nipping
- Grade III: flame hemorrhages, soft exudates (cotton-wool spots)
- Grade IV: papilledema → hypertensive emergency
6. LIFESTYLE MODIFICATIONS (Non-Pharmacological Treatment)
Every hypertensive patient should be counseled on lifestyle modification - these alone can reduce BP significantly:
| Intervention | Expected SBP Reduction |
|---|---|
| Weight loss (to ideal BMI <25) | ~1 mmHg per kg lost |
| DASH diet (fruits, vegetables, whole grains, low-fat dairy, low sodium) | ~8-14 mmHg |
| Sodium restriction (<2.3 g/day, ideally <1.5 g/day) | ~5-6 mmHg |
| DASH + low sodium combined | Up to ~20.8 mmHg in SBP ≥150 mmHg |
| Aerobic exercise (150 min/week moderate intensity) | ~5-8 mmHg |
| Potassium supplementation or high-potassium diet | ~3-5 mmHg |
| Limit alcohol (<2 drinks/day men, <1 drink/day women) | ~3-4 mmHg |
| Smoking cessation | Reduces overall CV risk (acute pressor effect) |
Physical activity dose-dependently reduces HTN risk by ~6% per 10 MET-hours/week of leisure activity.
7. PHARMACOLOGICAL TREATMENT
When to Start Medications
| BP Stage | No TOD/Risk Factors | With TOD or high CVD risk |
|---|---|---|
| Elevated BP (120-129/<80) | Lifestyle only | Lifestyle only |
| Stage I (130-139/80-89) | Lifestyle ± medication (if 10-yr CVD risk ≥10%) | Start medication |
| Stage II (≥140/90) | Start medication + lifestyle | Start medication + lifestyle |
| ≥160/100 | Two-drug combination | Two-drug combination |
First-Line Drug Classes
| Class | Examples | Mechanism | Preferred In |
|---|---|---|---|
| ACE Inhibitors | Lisinopril, ramipril, enalapril | Block Ang I→Ang II conversion | DM, CKD with proteinuria, HFrEF, post-MI |
| ARBs | Losartan, valsartan, irbesartan | Block AT1 receptor | Same as ACEI; better tolerated (no cough) |
| Thiazide/Thiazide-like diuretics | HCTZ, chlorthalidone, indapamide | Block NCC in DCT → natriuresis | Elderly, Black patients, isolated systolic HTN; chlorthalidone preferred |
| Calcium Channel Blockers (CCB) | Amlodipine (DHP); diltiazem, verapamil (non-DHP) | Block L-type Ca channels → vasodilation (DHP) or rate/conduction (non-DHP) | Elderly, Black patients, angina, isolated systolic HTN |
| Beta-blockers | Metoprolol, carvedilol, bisoprolol | Block β-adrenergic receptors → ↓CO, ↓renin | Post-MI, HF, angina, tachyarrhythmia; NOT first-line for uncomplicated HTN per 2025 AHA/ACC |
| Aldosterone antagonists (MRA) | Spironolactone, eplerenone | Block aldosterone receptor | Primary aldosteronism, resistant HTN, HFrEF |
| Alpha-1 blockers | Doxazosin, prazosin | Block α1 receptors → vasodilation | BPH + HTN; not first-line |
| Central agonists | Clonidine, methyldopa | ↓Sympathetic outflow (α2 agonist) | Resistant HTN; methyldopa = drug of choice in pregnancy (with labetalol/nifedipine) |
| Vasodilators | Hydralazine, minoxidil | Direct arterial vasodilation | Refractory HTN; minoxidil for severe cases |
| ARNi | Sacubitril/valsartan | Block neprilysin + AT1 receptor | HFrEF with HTN |
Compelling Indications (Drug of Choice)
| Condition | Preferred Agent(s) | Avoid |
|---|---|---|
| Diabetes | ACEI or ARB | |
| CKD with proteinuria | ACEI or ARB | |
| Heart failure (HFrEF) | ACEI/ARB + beta-blocker + MRA | Non-DHP CCB (verapamil, diltiazem) |
| Post-MI | Beta-blocker + ACEI | |
| Atrial fibrillation (rate control) | Beta-blocker or non-DHP CCB | |
| Angina | Beta-blocker or CCB | |
| Isolated systolic HTN (elderly) | Diuretic or DHP-CCB | |
| Primary aldosteronism | MRA (spironolactone) | |
| Pregnancy | Labetalol, methyldopa, nifedipine | ACEI, ARB (teratogenic) |
| Black patients | Thiazide + CCB (ACEI less effective as monotherapy) | |
| Renovascular HTN (bilateral RAS) | CCB, diuretic | ACEI/ARB (risk of acute kidney injury) |
BP Targets
| Population | Target |
|---|---|
| General adults | <130/80 mmHg (AHA/ACC 2025) |
| Adults ≥65 years | <130/80 mmHg if tolerated (individualize) |
| CKD with proteinuria | <130/80 mmHg |
| Diabetes | <130/80 mmHg |
| Stroke prevention | <130/80 mmHg |
| Pregnancy | <140/90 (severe HTN: <160/110) |
ESC 2024 target: SBP 120-129 mmHg if tolerated for most adults; elderly target 130-139 mmHg SBP.
8. RESISTANT HYPERTENSION
Definition: BP ≥130/80 (or uncontrolled) despite ≥3 drugs at optimal doses (including a diuretic)
Steps in management:
- Confirm true resistance (exclude pseudoresistance - poor adherence, white coat effect, incorrect measurement)
- Optimize current regimen (especially add/up-titrate diuretic - chlorthalidone preferred over HCTZ)
- Screen for secondary causes (especially primary aldosteronism - most common reversible cause)
- Add MRA (spironolactone) as 4th agent - evidence from PATHWAY-2 trial
- Consider direct vasodilators (hydralazine, minoxidil)
- 42% of treatment-resistant hypertensives are physically inactive
- Device-based therapies: renal denervation (investigational but promising)
9. HYPERTENSIVE EMERGENCIES
Definition
BP usually >180/120 mmHg with acute TOD:
- Hypertensive encephalopathy: headache, confusion, vomiting, altered consciousness, papilledema
- Hypertensive ICHD / Hemorrhagic stroke
- Acute coronary syndrome (ACS)
- Acute aortic dissection
- Acute pulmonary edema
- Acute kidney injury
- HELLP syndrome / Eclampsia
- Thrombotic microangiopathy (TMA)
Management Principles
- Do NOT lower BP too rapidly - risk of ischemia due to shifted autoregulation
- Target: reduce MAP by not more than 25% in the first hour, then to 160/100-110 mmHg over 2-6h, then normalize over 24-48h
- Exception - Aortic dissection: target SBP 100-120 mmHg within minutes
IV Agents for Hypertensive Emergencies
| Drug | Mechanism | Best For | Avoid |
|---|---|---|---|
| Nicardipine | DHP-CCB | Most emergencies; ACS, stroke, encephalopathy | |
| Labetalol | α+β blocker | ACS, aortic dissection, perioperative | Acute HF, bronchospasm |
| Esmolol | Ultra-short β1-blocker | Aortic dissection, perioperative | |
| Clevidipine | Ultra-short DHP-CCB | Perioperative, wide applications | |
| Nitroprusside | NO donor → arterial + venous dilation | Most emergencies | Caution: cyanide toxicity, ↑ICP |
| Nitroglycerin | Venous dilation > arterial | ACS, pulmonary edema | |
| Hydralazine | Direct vasodilator | Eclampsia/pregnancy | Unpredictable response |
| Phentolamine | Alpha blocker | Pheochromocytoma, MAOI crisis | |
| Fenoldopam | D1 agonist | CKD (renal protective) |
10. SPECIAL POPULATIONS
HTN in Pregnancy
- Gestational HTN: onset ≥20 weeks without proteinuria
- Preeclampsia: ≥20 weeks + proteinuria (>300 mg/24h) ± severe features (headache, visual changes, epigastric pain, thrombocytopenia, elevated LFTs)
- Eclampsia: preeclampsia + seizures
- HELLP: Hemolysis, Elevated Liver enzymes, Low Platelets
- Treatment: labetalol IV, hydralazine IV, oral nifedipine; magnesium sulfate for seizure prophylaxis/treatment
- ACEI and ARBs are absolutely contraindicated (fetal renal agenesis, oligohydramnios, death)
HTN in Elderly
- Predominantly isolated systolic HTN (ISH) due to large artery stiffness
- Pulse pressure increases with age as a marker of arteriosclerosis
- Start with low doses, titrate slowly
- Orthostatic hypotension is common - check standing BP
- Target: SBP <130-139 mmHg; individualize based on frailty
HTN in CKD
- CKD is both a cause and consequence of HTN
- Proteinuric CKD: ACEI/ARB preferred (reduce intraglomerular pressure)
- Monitor potassium and creatinine after starting ACEI/ARB (acceptable ≤30% creatinine rise)
HTN in Diabetes
- Most patients with T2DM have HTN (~85%)
- ACEI/ARB preferred (nephroprotective, reduce microalbuminuria)
- Target: <130/80 mmHg
11. TARGET ORGAN DAMAGE & COMPLICATIONS
| Organ | Complication | Mechanism |
|---|---|---|
| Heart | LVH, CAD, HF, AF | Pressure overload → concentric hypertrophy → diastolic dysfunction → HF |
| Brain | Ischemic stroke, hemorrhagic stroke, TIA, vascular dementia | Large artery atherosclerosis + small vessel lipohyalinosis |
| Kidneys | Nephrosclerosis, CKD, ESRD | Preglomerular vasoconstriction → ischemic nephropathy |
| Eyes | Hypertensive retinopathy, BRVO/CRVO | Arterial wall thickening, AV nipping |
| Aorta | Dissection, aneurysm | Wall stress ∝ BP × radius |
| Peripheral arteries | PAD | Accelerated atherosclerosis; 2.5x risk in men, 3.9x in women (Framingham) |
12. MONITORING & FOLLOW-UP
- After initiating therapy: recheck BP in 1-4 weeks
- Once controlled: every 3-6 months
- Annual labs: BMP (potassium monitoring on diuretics/ACEI/ARB), fasting glucose, lipids, urinalysis
- Adherence assessment at every visit
- Reassess for new secondary causes if BP deteriorates after stability
KEY MNEMONICS
ABCD for antihypertensive selection:
- A = ACE inhibitor / ARB
- B = Beta-blocker (if compelling indication)
- C = Calcium channel blocker
- D = Diuretic (thiazide)
Secondary HTN causes - "PHEO CRASH":
- Primary aldosteronism
- Hypo/hyperthyroidism
- Endocrine (Cushing, acromegaly, hyperCa)
- OSA (obstructive sleep apnea)
- Coarctation of aorta
- Renovascular disease (RAS)
- Acute/chronic kidney disease (renal parenchymal)
- Sleek (i.e., drugs - Sympathomimetics, NSAIDs, OCPs, Steroids)
- Hypercalcemia / pheocHromocytoma
RECENT GUIDELINES UPDATE (2025)
2025 AHA/ACC Guideline (PMID: 40811516 - published October 2025):
- Replaces the 2017 ACC/AHA guideline
- Maintained definition of HTN as ≥130/80 mmHg
- Emphasizes living document approach with ongoing updates
- Reaffirms universal BP target of <130/80 for most adults
- Strengthened evidence for lifestyle intervention combinations
2024 ESC Guideline (PMID: 39210715 - published October 2024):
- Maintains definition of HTN as ≥140/90 mmHg
- Introduces "elevated BP" category: 130-139/85-89 mmHg
- Recommends treatment initiation target SBP 120-129 mmHg in most adults
Sources: Fuster and Hurst's The Heart, 15th Edition; Frameworks for Internal Medicine; Textbook of Family Medicine 9e; 2025 AHA/ACC Hypertension Guideline (PMID: 40811516); 2024 ESC Guidelines (PMID: 39210715)
Generate a clinical decision tree for secondary hypertension workup
Generating Image
Here is the full clinical decision tree for secondary hypertension workup. Here's a quick walkthrough of the logic:
How to Use This Tree
Step 1 - Screen for Red Flags (any one = investigate secondary cause):
- Age <30, non-obese
- Resistant HTN (≥3 drugs, one a diuretic)
- Acute BP rise from previously stable readings
- Unprovoked hypokalemia
- Abdominal bruit
- Episodic symptoms (headache + palpitations + diaphoresis)
- Onset before puberty
Step 2 - Route to the relevant branch:
| Branch | Key Clinical Clue | First Test |
|---|---|---|
| Renovascular | Abdominal bruit, ↑Cr after ACEi/ARB, young woman | Duplex renal USS |
| Renal Parenchymal | Abnormal UA, ↑Cr, proteinuria | Renal USS + 24h urine protein |
| Primary Aldosteronism | Hypokalemia + metabolic alkalosis | Aldosterone:Renin ratio (>30 = positive) |
| Pheochromocytoma | Episodic "5 Ps" (pressure, pain, perspiration, palpitations, pallor) | Plasma/24h urine metanephrines |
| Cushing's | Central obesity, striae, ecchymoses | Overnight 1mg dexamethasone suppression test or 24h urine cortisol |
| Thyroid disorder | TSH abnormal, wide pulse pressure (hyper) or raised DBP (hypo) | TSH + Free T4 |
| Coarctation | BP discordance arms vs. legs, rib notching on CXR | Echocardiogram or CT aorta |
| OSA | Snoring, nondipping pattern, daytime somnolence | Polysomnography |
| Drug-induced | Medication history | Medication review + withdrawal |
Step 3 - Treat the underlying cause - many forms resolve or significantly improve with targeted treatment (e.g., adrenalectomy for aldosteronoma, spironolactone for bilateral hyperplasia, thyroid hormone replacement for hypothyroidism).
This is a shared conversation. Sign in to Orris to start your own chat.